nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—SLC6A2—sympathetic nervous system—adrenal gland cancer	0.123	0.308	CbGeAlD
Dexmedetomidine—CYP1A2—urine—adrenal gland cancer	0.052	0.13	CbGeAlD
Dexmedetomidine—CYP2E1—urine—adrenal gland cancer	0.0468	0.117	CbGeAlD
Dexmedetomidine—CYP2D6—urine—adrenal gland cancer	0.037	0.0924	CbGeAlD
Dexmedetomidine—ADRA2C—adrenal cortex—adrenal gland cancer	0.0159	0.0396	CbGeAlD
Dexmedetomidine—SLC6A2—gonad—adrenal gland cancer	0.0148	0.037	CbGeAlD
Dexmedetomidine—ADRA2C—cardiac atrium—adrenal gland cancer	0.0131	0.0328	CbGeAlD
Dexmedetomidine—SLC6A2—adrenal gland—adrenal gland cancer	0.0129	0.0323	CbGeAlD
Dexmedetomidine—ADRA2C—pituitary gland—adrenal gland cancer	0.0128	0.032	CbGeAlD
Dexmedetomidine—ADRA2C—adrenal gland—adrenal gland cancer	0.0115	0.0286	CbGeAlD
Dexmedetomidine—CYP1A1—cardiac atrium—adrenal gland cancer	0.0112	0.028	CbGeAlD
Dexmedetomidine—ADRA2A—gonad—adrenal gland cancer	0.0105	0.0262	CbGeAlD
Dexmedetomidine—ADRA2A—cardiac atrium—adrenal gland cancer	0.0105	0.0261	CbGeAlD
Dexmedetomidine—ADRA2A—pituitary gland—adrenal gland cancer	0.0102	0.0255	CbGeAlD
Dexmedetomidine—ADRA2A—adrenal gland—adrenal gland cancer	0.00914	0.0228	CbGeAlD
Dexmedetomidine—CYP2E1—adrenal gland—adrenal gland cancer	0.00894	0.0223	CbGeAlD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00139	0.00232	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00137	0.00229	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00137	0.00228	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—GNAS—adrenal gland cancer	0.00137	0.00228	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Biological oxidations—POMC—adrenal gland cancer	0.00136	0.00227	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—SPARC—adrenal gland cancer	0.00135	0.00226	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00135	0.00226	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00134	0.00223	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—TSHR—adrenal gland cancer	0.00133	0.00223	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GNRHR—adrenal gland cancer	0.00133	0.00222	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00133	0.00221	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—adrenal gland cancer	0.00133	0.00221	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—adrenal gland cancer	0.00133	0.00221	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—SDHB—adrenal gland cancer	0.00132	0.00221	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00129	0.00215	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Biological oxidations—POMC—adrenal gland cancer	0.00128	0.00214	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—CDC42—adrenal gland cancer	0.00128	0.00213	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—GNAS—adrenal gland cancer	0.00128	0.00213	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00126	0.00211	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	0.00126	0.0021	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—GNAS—adrenal gland cancer	0.00126	0.00209	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GNRHR—adrenal gland cancer	0.00125	0.00208	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00124	0.00207	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00124	0.00207	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00124	0.00207	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	0.00124	0.00206	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.00124	0.00206	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—IGF2—adrenal gland cancer	0.00123	0.00206	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GNRHR—adrenal gland cancer	0.00123	0.00204	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—GNAS—adrenal gland cancer	0.00122	0.00204	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00122	0.00204	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—SDHB—adrenal gland cancer	0.00121	0.00203	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00121	0.00201	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—TSHR—adrenal gland cancer	0.0012	0.00201	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—CDC42—adrenal gland cancer	0.00119	0.00199	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00117	0.00194	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00116	0.00193	CbGpPWpGaD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—POMC—adrenal gland cancer	0.00115	0.00192	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—IGF2—adrenal gland cancer	0.00115	0.00192	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—SDHB—adrenal gland cancer	0.00114	0.00191	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PRKACA—adrenal gland cancer	0.00114	0.00191	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—GNAS—adrenal gland cancer	0.00114	0.0019	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00114	0.0019	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00113	0.00188	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00113	0.00188	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—TSHR—adrenal gland cancer	0.00113	0.00188	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00111	0.00185	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—TSHR—adrenal gland cancer	0.00111	0.00185	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00109	0.00182	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00107	0.00179	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—RRM1—adrenal gland cancer	0.00105	0.00175	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—SDHD—adrenal gland cancer	0.00105	0.00175	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—GNAS—adrenal gland cancer	0.00104	0.00173	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00103	0.00171	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.00102	0.0017	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—POMC—adrenal gland cancer	0.00102	0.0017	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GNRHR—adrenal gland cancer	0.00101	0.00169	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00101	0.00168	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—CDC42—adrenal gland cancer	0.00097	0.00162	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	0.000964	0.00161	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000958	0.0016	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00094	0.00157	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—IGF2—adrenal gland cancer	0.000935	0.00156	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—GNAS—adrenal gland cancer	0.000927	0.00155	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—POMC—adrenal gland cancer	0.00092	0.00153	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000916	0.00153	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—TSHR—adrenal gland cancer	0.000914	0.00153	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000901	0.0015	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000895	0.00149	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GNRH1—adrenal gland cancer	0.000885	0.00148	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000884	0.00148	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000865	0.00144	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—SDHB—adrenal gland cancer	0.000862	0.00144	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—POMC—adrenal gland cancer	0.000859	0.00143	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000855	0.00143	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—RRM1—adrenal gland cancer	0.000852	0.00142	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—SDHD—adrenal gland cancer	0.000852	0.00142	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.000848	0.00141	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—POMC—adrenal gland cancer	0.000845	0.00141	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Biological oxidations—POMC—adrenal gland cancer	0.000817	0.00136	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CDC42—adrenal gland cancer	0.000812	0.00136	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SPRY2—adrenal gland cancer	0.000809	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000808	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000808	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GNRH1—adrenal gland cancer	0.000799	0.00133	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000795	0.00133	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TSHR—adrenal gland cancer	0.000788	0.00132	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.000788	0.00131	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—SDHD—adrenal gland cancer	0.000783	0.00131	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—RRM1—adrenal gland cancer	0.000783	0.00131	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—MED12—adrenal gland cancer	0.000782	0.00131	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—GNAS—adrenal gland cancer	0.000776	0.0013	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000772	0.00129	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000755	0.00126	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GNRH1—adrenal gland cancer	0.000746	0.00124	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000743	0.00124	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MEN1—adrenal gland cancer	0.000741	0.00124	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—SDHD—adrenal gland cancer	0.000738	0.00123	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—RRM1—adrenal gland cancer	0.000738	0.00123	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GNRH1—adrenal gland cancer	0.000734	0.00122	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CDC42—adrenal gland cancer	0.000734	0.00122	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SPRY2—adrenal gland cancer	0.00073	0.00122	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SDHB—adrenal gland cancer	0.00073	0.00122	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000721	0.0012	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TSHR—adrenal gland cancer	0.000712	0.00119	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00071	0.00118	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—GNAS—adrenal gland cancer	0.000701	0.00117	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—POMC—adrenal gland cancer	0.000698	0.00116	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CDC42—adrenal gland cancer	0.000685	0.00114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SPRY2—adrenal gland cancer	0.000682	0.00114	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CDC42—adrenal gland cancer	0.000674	0.00113	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SPRY2—adrenal gland cancer	0.000671	0.00112	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MEN1—adrenal gland cancer	0.000669	0.00112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TSHR—adrenal gland cancer	0.000665	0.00111	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000656	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—GNAS—adrenal gland cancer	0.000655	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TSHR—adrenal gland cancer	0.000654	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—GNAS—adrenal gland cancer	0.000644	0.00108	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—MED12—adrenal gland cancer	0.000635	0.00106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MEN1—adrenal gland cancer	0.000625	0.00104	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MEN1—adrenal gland cancer	0.000615	0.00103	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000613	0.00102	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GNRH1—adrenal gland cancer	0.000606	0.00101	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000586	0.000977	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—MED12—adrenal gland cancer	0.000583	0.000974	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—POMC—adrenal gland cancer	0.000576	0.00096	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000575	0.000959	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PRKACA—adrenal gland cancer	0.000571	0.000952	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PRKACA—adrenal gland cancer	0.000566	0.000944	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CDC42—adrenal gland cancer	0.000557	0.000929	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—RRM1—adrenal gland cancer	0.000555	0.000927	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—SDHD—adrenal gland cancer	0.000555	0.000927	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SPRY2—adrenal gland cancer	0.000554	0.000925	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MED12—adrenal gland cancer	0.00055	0.000918	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TSHR—adrenal gland cancer	0.00054	0.000901	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—GNAS—adrenal gland cancer	0.000532	0.000887	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—POMC—adrenal gland cancer	0.000523	0.000872	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—POMC—adrenal gland cancer	0.00052	0.000867	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PRKACA—adrenal gland cancer	0.000511	0.000852	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MEN1—adrenal gland cancer	0.000508	0.000847	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	0.000492	0.00082	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—POMC—adrenal gland cancer	0.000485	0.00081	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDC42—adrenal gland cancer	0.00048	0.000801	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—POMC—adrenal gland cancer	0.000478	0.000797	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PRKACA—adrenal gland cancer	0.000477	0.000796	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—POMC—adrenal gland cancer	0.000472	0.000787	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—RRM1—adrenal gland cancer	0.00047	0.000785	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SDHD—adrenal gland cancer	0.00047	0.000785	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PRKACA—adrenal gland cancer	0.00047	0.000784	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PRKACA—adrenal gland cancer	0.000464	0.000773	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IGF2—adrenal gland cancer	0.000463	0.000772	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GNAS—adrenal gland cancer	0.000463	0.000772	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GNAS—adrenal gland cancer	0.000459	0.000765	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ABCB1—adrenal gland cancer	0.000454	0.000757	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IGF1R—adrenal gland cancer	0.000447	0.000746	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—POMC—adrenal gland cancer	0.000441	0.000735	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—POMC—adrenal gland cancer	0.000434	0.000724	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDC42—adrenal gland cancer	0.000433	0.000723	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PRKACA—adrenal gland cancer	0.000426	0.00071	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IGF2—adrenal gland cancer	0.000418	0.000697	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MED12—adrenal gland cancer	0.000414	0.000691	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GNAS—adrenal gland cancer	0.000414	0.000691	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDC42—adrenal gland cancer	0.000405	0.000675	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IGF1R—adrenal gland cancer	0.000404	0.000674	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PRKACA—adrenal gland cancer	0.000401	0.00067	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDC42—adrenal gland cancer	0.000398	0.000665	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—POMC—adrenal gland cancer	0.000394	0.000658	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	0.000392	0.000654	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—adrenal gland cancer	0.00039	0.000651	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF2—adrenal gland cancer	0.00039	0.000651	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PRKACA—adrenal gland cancer	0.000388	0.000647	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GNAS—adrenal gland cancer	0.000387	0.000645	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TERT—adrenal gland cancer	0.000385	0.000642	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF2—adrenal gland cancer	0.000384	0.000641	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GNAS—adrenal gland cancer	0.000381	0.000635	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF1R—adrenal gland cancer	0.000377	0.000629	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GNAS—adrenal gland cancer	0.000376	0.000627	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF1R—adrenal gland cancer	0.000371	0.000619	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ABCB1—adrenal gland cancer	0.000369	0.000615	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—adrenal gland cancer	0.000365	0.000608	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—POMC—adrenal gland cancer	0.000358	0.000597	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MED12—adrenal gland cancer	0.000351	0.000585	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TERT—adrenal gland cancer	0.000348	0.00058	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GNAS—adrenal gland cancer	0.000345	0.000576	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ABCB1—adrenal gland cancer	0.000339	0.000565	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—BAD—adrenal gland cancer	0.000335	0.000559	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDC42—adrenal gland cancer	0.000329	0.000549	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GNAS—adrenal gland cancer	0.000325	0.000543	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TERT—adrenal gland cancer	0.000325	0.000542	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TERT—adrenal gland cancer	0.00032	0.000533	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ABCB1—adrenal gland cancer	0.000319	0.000533	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF2—adrenal gland cancer	0.000317	0.000529	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GNAS—adrenal gland cancer	0.000314	0.000524	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	0.000314	0.000523	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—POMC—adrenal gland cancer	0.000311	0.00052	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—POMC—adrenal gland cancer	0.000309	0.000515	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1R—adrenal gland cancer	0.000306	0.000511	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—BRAF—adrenal gland cancer	0.000305	0.000509	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—BAD—adrenal gland cancer	0.000302	0.000505	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	0.000302	0.000504	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—adrenal gland cancer	0.000296	0.000494	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—adrenal gland cancer	0.000296	0.000493	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—BAD—adrenal gland cancer	0.000282	0.000471	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—POMC—adrenal gland cancer	0.000279	0.000465	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—BAD—adrenal gland cancer	0.000278	0.000464	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—BRAF—adrenal gland cancer	0.000275	0.000459	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—adrenal gland cancer	0.000267	0.000445	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TERT—adrenal gland cancer	0.000264	0.00044	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—POMC—adrenal gland cancer	0.00026	0.000434	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—BRAF—adrenal gland cancer	0.000257	0.000429	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—POMC—adrenal gland cancer	0.000256	0.000428	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	0.000256	0.000427	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—BRAF—adrenal gland cancer	0.000253	0.000422	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—POMC—adrenal gland cancer	0.000253	0.000422	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	0.00025	0.000417	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—adrenal gland cancer	0.000249	0.000416	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—adrenal gland cancer	0.000248	0.000414	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—adrenal gland cancer	0.000245	0.000409	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GNAS—adrenal gland cancer	0.000245	0.000408	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	0.00024	0.000401	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—POMC—adrenal gland cancer	0.000232	0.000388	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BAD—adrenal gland cancer	0.000229	0.000383	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—adrenal gland cancer	0.00022	0.000368	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—POMC—adrenal gland cancer	0.000219	0.000365	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—POMC—adrenal gland cancer	0.000212	0.000353	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—adrenal gland cancer	0.000209	0.000348	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GNAS—adrenal gland cancer	0.000207	0.000346	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	0.000204	0.00034	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—adrenal gland cancer	0.000202	0.000338	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—adrenal gland cancer	0.000202	0.000337	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000199	0.000332	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000186	0.00031	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—adrenal gland cancer	0.000185	0.000309	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000183	0.000305	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—adrenal gland cancer	0.000175	0.000291	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—adrenal gland cancer	0.000175	0.000291	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—POMC—adrenal gland cancer	0.000165	0.000275	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—adrenal gland cancer	0.000158	0.000263	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000151	0.000252	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—adrenal gland cancer	0.000147	0.000246	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—adrenal gland cancer	0.000147	0.000245	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—adrenal gland cancer	0.000145	0.000242	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—POMC—adrenal gland cancer	0.00014	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—adrenal gland cancer	0.000132	0.000221	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	0.000131	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—adrenal gland cancer	0.000124	0.000206	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—adrenal gland cancer	0.000122	0.000203	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—adrenal gland cancer	0.00012	0.0002	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	0.000111	0.000186	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—adrenal gland cancer	0.0001	0.000168	CbGpPWpGaD
